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Background: Assessment of cardiovascular disease (CVD) risk factors can predict clinical manifestations of
atherosclerosis in adulthood. In this pilot study with hypercholesterolemic children and adolescents, we
investigated the effects of a combination of plant sterols, fish oil and B vitamins on the levels of four independent
risk factors for CVD; LDL-cholesterol, triacylglycerols, C-reactive protein and homocysteine.
Methods: Twenty five participants (mean age 16 y, BMI 23 kg/m2) received daily for a period of 16 weeks an
emulsified preparation comprising plant sterols esters (1300 mg), fish oil (providing 1000 mg eicosapentaenoic acid
(EPA) plus docosahexaenoic acid (DHA)) and vitamins B12 (50 μg), B6 (2.5 mg), folic acid (800 μg) and coenzyme
Q10 (3 mg). Atherogenic and inflammatory risk factors, plasma lipophilic vitamins, provitamins and fatty acids were
measured at baseline, week 8 and 16.
Results: The serum total cholesterol, LDL- cholesterol, VLDL-cholesterol, subfractions LDL-2, IDL-1, IDL-2 and plasma
homocysteine levels were significantly reduced at the end of the intervention period (p<0.05). The triacylglycerols
levels decreased by 17.6%, but did not reach significance. No significant changes in high sensitivity C-reactive
protein, HDL-cholesterol and apolipoprotein A-1 were observed during the study period. After standardisation for
LDL cholesterol, there were no significant changes in the levels of plasma γ-tocopherol, β-carotene and retinol,
except for reduction in α-tocopherol levels. The plasma levels of n-3 fatty acids increased significantly with the
dietary supplementation (p<0.05).
Conclusions: Daily intake of a combination of plant sterols, fish oil and B vitamins may modulate the lipid profile of
hypercholesterolemic children and adolescents.
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Atherosclerotic cardiovascular disease is the number
one cause of death worldwide with over 2.0 million
deaths in the European Union and an estimated total
cost of €192 billion a year [1]. Atherosclerosis can begin
in childhood with the development of arterial fatty
streaks. Assessment of the independent risk factors for
CVD, particularly low density lipoprotein (LDL) choles-
terol in children and adolescents, can predict clinical
manifestations of atherosclerosis in adulthood and
therefore there is a growing demand for lipid screening
in childhood [2,3].
Improvements in diet and lifestyle can reduce CVD risk
factors, but failure to respond to such interventions can
result in pharmacological intervention in children from
the age of 8 years with the use of statins recommended for
LDL-cholesterol levels ≥190 mg/dl (≥4.9 mmol/l) or when
LDL-cholesterol ≥160 mg/dl (≥4.1 mmol/l) and additional
risk factors are present [3,4].
Plant sterols/stanols and n-3 long-chain polyunsatur-
ated fatty acids (PUFA) are increasingly being used for
the prevention and management of hypercholesterol-
emia, hyperlipidemia and other risk factors such as in-
flammation and thrombosis. The intakes of plant sterol/
stanol esters can reduce blood LDL-cholesterol levels in
children with familial hypercholesterolemia [5-7]. The
European Food Safety Authority (EFSA) has approved
the daily intake of 1.5 – 2.4 g of plant sterol/stanol esters
to achieve a blood LDL-cholesterol reduction of 7-10.5%
in 2-3 weeks in an adult population [8].
The cardioprotective effects of n-3 PUFA appear
to be due a multifaceted synergistic process involving
reduction of triacylglycerols (TAG), very-low-density
lipoprotein (VLDL), increasing levels of antiinflamma-
tion together with regulation of transcription factors
and gene expression, membrane fluidity and antiar-
rhythmic and antithrombotic effects [9]. In children
with hyperlipidemia, supplementation with DHA has
been found to be associated with a significant shift in
lipoprotein subclasses towards large, buoyant LDL par-
ticles and restoration of brachial artery endothelial
function [10,11].
Reduction of total homocysteine levels by folic acid,
vitamin B6 and vitamin B12 can contribute to the pre-
vention of CVD [12] and folic acid supplementation has
been found to reduce total homocysteine and high sensi-
tivity C-reactive protein (hsCRP) in children with familial
hypercholesterolemia [13].
Therefore, the combination of these natural com-
pounds may offer more comprehensive approach in the
early management of CVD risk factors.
This pilot study investigates the impact of a combin-
ation of plant sterols, fish oil and B vitamins on the
levels of four independent risk factors for CVD (LDL-cholesterol, TAG, hsCRP and homocysteine) in a group
of hypercholesterolemic children and adolescents.
Methods
Subjects
Thirty children and adolescents, registered with Juvena-
lia Pediatric Centre, Dunajska Streda, Slovakia, were
invited to participate in the study based on the universal
screening of cholesterol and glycaemia in children aged
11 and adolescents aged 17 according to Ministry of
Health guidelines MZ13010/2004. Written informed
consent was obtained from the parents or guardians be-
fore participating in the study. Subjects with initial total
cholesterol levels ≥ 4.1 mmol/l (≥159 mg/dl) [14] despite
completing a 3 month period of assigned dietary lifestyle
change were selected for inclusion in this study. Genetic
diagnosis of familial hypercholesterolemia or familial
combined hyperlipidemia had not been determined at
this stage of investigation. None of the subjects had
received lipid or cholesterol lowering drugs, were dia-
betic, hypertensive or had a history of cardiovascular
diseases.
Study design and dietary assessment
Ethical Approval was granted by the Medical School Eth-
ics Board, Comenius University in Bratislava, Slovakia
(2007). During the 16 week study period, participants
received daily two 5 ml doses of an emulsified preparation
of plant sterols esters (1300 mg) and fish oil (providing
590 mg EPA and 410 mg DHA) together with vitamins
B12 (50 μg), and B6 (2.5 mg), folic acid (800 μg) and
coenzyme Q10 (3 mg) supplied by Cultech Ltd., Port
Talbot, United Kingdom. The fatty acid composition of
the intervention was as follows: Myristic acid (14:0) 4.84%,
Palmitic acid (16:0) 10.76%, Palmitoleic acid (16:1) 3.67%,
Stearic acid (18:0) 4.05%, Oleic acid (18:1, n-9) 1.7%, Lino-
leic acid (18:2, n-6) 10.05%, Arachidonic acid (20:4, n-6)
1.8%, EPA (20:5, n-3) 24.08%, DHA (22:6, n-3) 16.32%,
Others 24.73%.
Compliance to product assessed from the weekly
records of daily intervention intake was 88.2%.
All subjects were instructed to maintain their usual
dietary and exercise patterns throughout the study
period and to monitor any changes during the study,
parents/guardians were asked to complete a participant
diet habit and physical activity pattern questionnaire at
baseline and upon completion of the study. The ques-
tionnaire consisted of 4 questions on meal and drink
patterns, 9 questions on the intake of various foods that
are a common part of a typical diet in the country and 3
questions relating to physical activities. Data on food in-
take and physical activity were expressed as frequencies
ranging from several times per day to never. The ques-
tionnaires were assessed using a scoring system and
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study were compared.
Compliance
Of the thirty subjects, five withdrew from the study due
to product palatability or nausea. Twenty five subjects
therefore completed the intervention.
Clinical and anthropometric assessment
Resting blood pressure levels were measured in the left
arm in the sitting position by sphygmomanometer
(Omron M3, Intellisense, Japan). Body weight and height
were measured without shoes and with light clothing
using a digital weighing and measuring station with auto-
matic body mass index (BMI) calculation (kg/m2, SECA
764, Germany). Overweight was defined as BMI ≥ 90 per-
centile on the age- and gender-specific BMI for age
growth chart and obese as BMI ≥ 97 percentile. Waist cir-
cumferences were measured in cm with an inelastic tape
to the nearest mm, with the subject in a standing position.
Biochemical analysis
Venous blood samples were collected after 12-hours over-
night fast. Within 1 h of collection, blood was centrifuged
(1200 x g, 10 min), serum and plasma (EDTA as an anti-
coagulant) were obtained and frozen at -80°C until analysis.
The fasting serum analysis of total cholesterol, TAG,
hsCRP, apolipoprotein A-1 and glucose was determined
at an accredited Clinical biochemistry and haematology
laboratory using a Hitachi 911 Analyzer (Roche Diagnos-
tics, Switzerland). Lipoproteins were determined by
LipoprintW LDL system (Quantimetrix Corp. CA, USA)
according to manufacturer’s instructions. The athero-
genic lipoprotein profile is characterised by the presence
of VLDL, IDL-1 (intermediate density), IDL-2 and small
dense LDL-3 to LDL-7 subfractions [15].
Plasma homocysteine, methionine and cysteine were
determined on a HPLC system [16,17]. The internal stand-
ard (penicillamine) and sodium borohydride (1 mol/l in
0.1 mol/l NaOH) were added to 100 μl of plasma, mixed
and incubated at 50°C for 30 minutes. Perchloric acid in
EDTA (0.6 mol/l in 1 mmol/l) was added and samples cen-
trifuged at 14,000 rpm for 5 minutes. The supernatant was
diluted 1:1 ratio into the mobile phase (50 mmol/l sodium
phosphate, 1.0 mmol/l ion-pairing reagent 1-octanesulfonic
acid and 6% acetonitrile (v/v), adjusted to pH 2.7 with 85%
phosphoric acid) and injected (50 μl) onto a PurospherW
STAR RP-18e column (250x4.6 mm I.D., 5 μm, Merck) at
a flow rate of 0.8 ml/min at ambient temperature with a
Coulochem II detector (ESA, USA) equipped with an ana-
lytical cell (model 5010A) and a guard cell (model 5020).
Plasma α-tocopherol, γ-tocopherol, β-carotene and
retinol were determined by a reversed phase HPLC
method [18] using a Nucleosil 120-5 C18 column(250x4.6 mm, 5 μm I.D., protected by a Nucleosil C18 pre-
column, Watrex, Czech Republic) with fluorescent detector
(0-4 min at 330/470 excitation/emission; 4.1-20 min T 298/
328) and detector in the visible range at 450 nm (Watrex,
Czech Republic). Flow injection was 20 μl. The mobile
phase consisted of acetonitrile:tetrahydrofuran:methanol
containing BHT:1% ammonium acetate (67.4 : 22 : 6.8 : 3.8,
v/v/v/v). Flow rate was 1.2 ml/min and column oven was
set at 29°C.
Fatty acid methyl esters (FAME) were prepared using an
adaptation of a method previously reported [19]. The
extracted lipid sample (75 μl) was incubated with 2.5%
sulphuric acid in dry methanol: toluene (2:1 v/v) for 2 h at
70°C. FAME were extracted using hexane, dried down
under nitrogen and resuspended in isooctane. The FAME
were analysed by gas chromatography using an Agilent
Technologies 6890 N gas chromatograph, fitted with a
7683 series injector and an Elite-225 column (30 m x
0.25 mm I.D., 0.25 μm film thickness; Perkin Elmer, USA).
The column temperature was 170°C for 3 min to 220°C at
4°C/min, hydrogen as carrier gas (1.1 ml/min). The FAME
were identified by comparison of their retention times
with standards (Sigma, Dorset, UK) and nonadecanoic
acid (C19:0) was used as an internal standard.
The intraassay coefficient of variation (CV) for mea-
sured parameters ranged between 0.8 to 6.8% and the
interassay CV range was between 1.2 to 10.5%.
Statistical analysis
Data were analysed by a mixed model, taking account of
repeated measurements. In this model, the visit (week=0,
8 and 16) was treated as a fixed effect whereas the subject
was treated as a random effect. During the study, some
subjects dropped out, resulting in some incomplete obser-
vations which were not imputed but were assumed to be
missing at random in the mixed model analysis. The esti-
mated differences between week 8, 16 and baseline were
derived from the mixed model and were reported together
with their 95% confidence intervals. Reported P-values are
two-sided and a P-value of <0.05 was considered statisti-
cally significant, and all statistical analyses were carried
out by using the Statistical Analysis System (SAS) version
9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
The baseline characteristics for the total population and the
screening age groups are shown in Table 1. In addition,
baseline characteristics of the subjects by gender are pre-
sented in Additional file 1: Table S1. Among the subjects,
16/25 girls (81.2% menstruating) and 9/25 boys, 20%
(5 boys) were considered overweight and 12% (2 boys/1
girl) obese. 12 subjects had waist circumference and 11 had
blood pressure levels above the reference range [14]; fasting
glucose levels were acceptable (range: 3.8 - 5.8 mmol/l).
Table 1 Baseline characteristics of subjectsa
Parameter All 10-16 years old ≥ 17 years old
(n=25) (n=10) (n=15)
Age (years) 16.37 (3.75) 11.56 (1.34) 18.43 (1.08)
Weight (kg) 63.66 (23.49) 51.60 (19.00) 71.70 (23.26)
BMI (kg/m2) 22.99 (6.10) 21.10 (6.10) 24.26 (5.97)
Overweight (n) 5/25 2/10 3/15
Obese (n) 3/25 1/10 2/15
Waist circumference (cm) 85.18 (15.58) 80.55 (13.89) 88.27 (16.33)
Fasting Glucose (mmol/l) 4.97 (0.48) 5.01 (0.29) 4.94 (0.59)
Blood Pressure
Systolic (mmHg) 122.60 (13.78) 120.00 (7.82) 124.33 (16.68)
Diastolic (mmHg) 78.80 (9.38) 79.00 (6.99) 78.67 (10.93)
aData presented as mean (standard deviation); n- number of subjects per group.
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levels decreased significantly by 3.59% (P=0.0457) and
4.02% (P =0.0275), respectively with no change in the
diastolic blood pressure. BMI increased significantly
(P=0.0498) only in adolescents aged 17 and over.
Atherogenic and inflammatory risk markers
Significant reductions in Total cholesterol (7.74%), LDL-
cholesterol (8.45%) and VLDL-cholesterol (19%) were
observed at 16 weeks with no change in HDL-choles-
terol, apolipoprotein A1 or hsCRP levels (Table 2). TAG
levels decreased over 16 weeks by 17.6%, but did not
reach significance. Homocysteine and methionine levels
were significantly lower at week 16 (P<0.0001 for both),
whilst cysteine levels increased (P=0.0002).
Analysis of cholesterol subfractions showed significant
reduction in IDL-1, IDL-2 and LDL-2 levels at week 16
compared to baseline (Table 2). LipoprintW profiles for all
participants are presented in Additional file 2: Table S2.
Subgroup analysis on the basis of age indicates a sig-
nificant reduction in the Total cholesterol, LDL-
cholesterol and LDL-2 subfraction in adolescents over
17 years old at week 16 (P=0.0049, P=0.0176 and P
=0.0264, respectively), but only a trend towards signifi-
cance in the younger age group (P=0.0783 for Total
cholesterol and P=0.0833 for LDL-cholesterol). Signifi-
cant reductions were recorded after 16 weeks in both
age groups for VLDL-cholesterol and homocysteine
levels (P for all <0.05). In addition, there was a marked
reduction in the TAG levels, which reached significance
for the 10-16 year old children (P=0.0355). No signifi-
cant changes in hsCRP, HDL-cholesterol and apolipo-
protein A1 were observed in either age group.
PUFA profile
Plasma levels of EPA and DHA increased significantly
over the study period by 220% and 130% (Table 3),
whereas the levels of arachidonic acid (AA) anddihomo-γ-linolenic acid (DGLA) decreased significantly
by 18% and 21%, respectively.
Vitamins and provitamins
Reductions in plasma α-tocopherol (19.2%) and retinol
(19.5%) levels were observed at the end of the interven-
tion period with no changes in the levels of γ-tocopherol
and β-carotene (Table 4). After standardisation for LDL
cholesterol, only significant reduction was detected for
α-tocopherol (P=0.0210).
Background diet
No significant differences in dietary habits and physical
activity patterns were observed over the study period
(P=0.669, F=0.188), indicating that the changes in lipid
profiles were unlikely to be the result of dietary alteration.
Discussion
The present study shows that the combination of plant
sterol esters (1300 mg), fish oil (1000 mg EPA+DHA)
and B vitamins impacts on LDL-cholesterol and homo-
cysteine levels in hypercholesterolemic children and ado-
lescents. To our knowledge, this is the first report of the
use of the combination of these natural compounds for
early dietary management of potential CVD risk.
Elevated LDL-cholesterol level is a well-established in-
dependent risk factor for CVD. Reductions in the LDL-
cholesterol levels by 8.7% in the group of 15 adolescents
aged over 17 years and by 9.5% in the group of 10 chil-
dren aged 10 to 16 years were observed. The results are
in line with previous studies on the use of plant sterols
and stanols in children and adolescents with hyperchol-
esterolemia with the significant LDL-cholesterol reduc-
tion observed in range of 9 to 15% with daily intake
ranging from 1.2 to 3 g of plant sterol or stanols
[5-7,20,21]. It has been proposed that the mechanism of
such cholesterol lowering involves competition between
intestinal plant sterols/stanols and intestinal cholesterol
Table 2 Serum lipids and other atherogenic and inflammatory risk markers
Parameter Baseline mean (SD) Change at week 8 95% CI P-value Change at week 16 95% CI P-value
Total-C (mg/dl)a 205.56 (44.10) -5.96 -15.19 to 3.27 0.2005 -15.92 -25.15 to -6.69 0.0011
LDL-C (mg/dl)a 124.52 (38.20) -2.96 -9.84 to 3.92 0.3912 -10.52 -17.40 to -3.64 0.0035
HDL-C (mg/dl)a 52.04 (10.83) -1.96 -5.48 to 1.56 0.2683 0.32 -3.20 to 3.84 0.8557
Atherogenic Index 4.08 (1.08) 0.02 -0.25 to 0.28 0.8940 -0.36 -0.62 to -0.09 0.0095
TAG (mmol/l) 1.42 (0.66) 0.22 -0.17 to 0.61 0.2586 -0.24 -0.63 to 0.15 0.2191
Apolipoprotein A1 (g/l) 1.50 (0.25) 0.05 -0.04 to 0.14 0.3073 0.02 -0.07 to 0.11 0.7086
hsCRP (mg/l) 1.86 (2.03) -0.11 -1.05 to -0.83 0.8159 0.86 0.08 to 1.81 0.0729
Homocysteine (μmol/l) 8.51 (3.14) -2.88 -3.61 to -2.14 <0.0001 -3.25 -3.98 to -2.51 <0.0001
Methionine (μmol/l) 28.55 (4.32) -5.13 -7.14 to -3.13 <0.0001 -8.58 -10.59 to -6.57 <0.0001
Cysteine (μmol/l) 173.87 (33.25) 44.00 25.98 to 62.03 <0.0001 36.37 18.34 to 54.39 0.0002
Lipoprotein Subfractions (mg/dl)a
VLDL 28.84 (6.34) -1.08 -3.86 to 1.70 0.4378 -5.48 -8.26 to -2.70 0.0002
IDL-1 28.48 (10.02) -1.88 -4.40 to 0.64 0.1399 -5.20 -7.72 to -2.68 0.0001
IDL-2 11.12 (4.21) -0.12 -1.25 to 1.01 0.8322 -2.08 -3.21 to -0.95 0.0006
IDL-3 16.40 (7.71) 3.04 0.31 to 5.77 0.0297 -1.08 -3.81 to 1.65 0.4299
LDL-1 47.60 (14.78) 0.48 -3.80 to 4.76 0.8226 1.28 -3.00 to 5.56 0.5505
LDL-2 19.60 (13.44) -4.68 -7.84 to -1.52 0.0045 -3.44 -6.60 to -0.28 0.0335
LDL-3 1.32 (1.93) -0.08 -1.02 to 0.86 0.8642 0.00 -0.94 to 0.94 1.0000
Data are presented as mean (standard deviation);
C - cholesterol; LDL - low density lipoprotein; HDL - high density lipoprotein; Atherogenic Index – Total cholesterol:HDL cholesterol; TAG – triacylglycerols; hsCRP-
high sensitivity C-reactive protein; VLDL - very low density lipoprotein; IDL - intermediate density lipoprotein,
aTo change to mmol/l, multiply the value with 0.02586.
P-value derived with mixed model.
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enterocyte ATP-binding cassette transport proteins [22].
The atherogenic index (Total cholesterol to HDL-choles-
terol ratio) improved during the study with no significant
change in HDL-cholesterol, apolipoprotein A-1 and hsCRP.
Measurement of LDL subfractions may provide add-
itional assessment of CVD risk. There is growing evi-
dence that small dense LDL subfractions may be more
atherogenic than larger less dense LDL subfractions due
to their lower binding affinity for the LDL receptor,
impaired clearance from the circulation, susceptibility toTable 3 Polyunsaturated fatty acids profile in plasma
Parameter (μg FA/ml) Baseline mean (SD) Change at week 8 95%
ALA 13.50 (8.50) -2.08 -4.71
EPA 8.73 (4.09) 17.96 12.42
DPA 8.24 (2.88) 3.63 2.10
DHA 32.91 (8.24) 18.39 12.05
EPA+DHA 41.63 (10.68) 36.35 25.16
LA 624.25 (137.45) 7.30 -52.7
GLA 10.01 (4.40) 0.75 -1.83
DGLA 35.07 (13.03) -3.32 -7.89
AA 148.24 (38.47) -11.57 -27.3
Data are presented as mean (standard deviation);
FA- fatty acid; ALA – α-linolenic acid, 18:3 (n-3); EPA – eicosapentaenoic acid, 20:5 (
22:6 (n-3); LA – linoleic acid, 18:2 (n-6); GLA – γ-linolenic acid, 18:3 (n-6); DGLA – dih
derived with mixed model.oxidative modification and easier penetration into the
subendothelial space of the arterial wall, leading more
readily to the formation of cholesterol deposits and in-
flammation [23]. In the present study, the combined ef-
fect of plant sterol esters, n-3 PUFA and B vitamins
resulted in less atherogenic profile. The levels of the
atherogenic lipoprotein VLDL, IDL-1 and IDL-2 subfrac-
tions decreased significantly in both age groups. How-
ever, only trace levels of the LDL-3 subfraction were
found in 15 participants (2 in the age group 10-16 years)
with no LDL-4 to LDL-7 subfractions detected. InCI P-value Change at week 16 95% CI P-value
to 0.56 0.1194 -3.71 -6.35 to -1.08 0.0067
to 23.50 <0.0001 10.47 4.93 to 16.00 0.0004
to 5.16 <0.0001 0.56 -0.97 to 2.09 0.4665
to 24.73 <0.0001 9.93 3.60 to 16.27 0.0028
to 47.55 <0.0001 20.40 9.21 to 31.6 0.0006
5 to 67.34 0.8081 -55.81 -115.86 to 4.24 0.0678
to 3.32 0.5615 -1.55 -4.12 to 1.03 0.2330
to 1.25 0.1550 -7.50 -12.07 to -2.93 0.0018
7 to 4.24 0.1477 -26.56 -42.37 to -10.76 0.0015
n-3); DPA – docosapentaenoic acid, 22:5 (n-3); DHA – docosahexaenoic acid,
omo-γ-linolenic acid, 20:3 (n-6); AA – arachidonic acid, 20:4 (n-6); P-value
Table 4 Lipophilic vitamins and provitamins
Parameter Baseline mean (SD) Change at week 8 95% CI P-value Change at week 16 95% CI P-value
α-Tocopherol (mg/l) 13.09 (3.49) -0.40 -1.65 to 0.85 0.5231 -2.52 -3.76 to -1.27 0.0002
α-Tocopherol/LDL-Ca 10.79 (3.38) -0.09 -1.26 to 1.08 0.8808 -1.39 -2.56 to -0.22 0.0210
γ-Tocopherol (mg/l) 0.69 (0.39) 0.51 0.27 to 0.76 0.0001 0.17 -0.08 to 0.42 0.1747
γ-Tocopherol/LDL-Ca 0.56 (0.37) 0.48 0.26 to 0.69 0.0001 0.18 -0.03 to 0.40 0.0938
Retinol (mg/l) 0.87 (0.28) -0.03 -0.13 to 0.07 0.5283 -0.17 -0.27 to -0.07 0.0015
Retinol/LDL-Ca 0.71 (0.25) 0.03 -0.08 to 0.13 0.6230 -0.07 -0.17 to 0.04 0.2099
β-Carotene (mg/l) 0.81 (0.91) -0.15 -0.43 to 0.12 0.2712 0.26 -0.53 to 0.02 0.0640
β-Carotene/LDL-Ca 0.63 (0.76) -0.11 -0.35 to 0.13 0.3708 -0.19 -0.43 to 0.05 0.1200
Data are presented as mean (standard deviation); aResults multiplied by 1000.
P-value derived with mixed model.
Garaiova et al. Nutrition Journal 2013, 12:7 Page 6 of 8
http://www.nutritionj.com/content/12/1/7addition, significant reductions in the predominant large
dense LDL-2 subfraction was observed in both age
groups without any change in non-atherogenic subfrac-
tions IDL-3 and LDL-1. In contrast to our results, Engler
et al. [11] reported significantly increased LDL-1 sub-
fraction by 91% and decreased small dense LDL-3 by
48% after supplementation with DHA (1.2 g/day) for
6 weeks in children with either initial LDL-cholesterol
levels above 130 mg/dl (familial hypercholesterolemia)
or LDL-cholesterol levels above 130 mg/dl or TAG
>150 mg/dl or both (familial combined hyperlipidemia).
To our knowledge there are no reports on the administra-
tion of plant sterols/stanols linked with LDL subfraction
analysis in children and adolescents. In hypercholesterole-
mic adults, following plant sterol and stanols supplementa-
tion in various forms and doses, the results are inconsistent
with no significant changes in LDL particle size [24] or a
significant reduction in all LDL subfractions [25] or small
LDL subfraction [26].
Accumulating evidence suggests that elevated plasma
TAG may pose another significant independent risk for
CVD [27]. The n-3 PUFA lowering effect on plasma TAG
levels is well established in adults, but no significant
changes in TAG levels in children and adolescents with
dyslipidemia were seen after daily supplementation with
1.2 g of DHA [10,11]. In our study, the TAG levels
decreased in both age groups, but a significant reduction
was observed in the group of children aged 10 to 16 (base-
line mean TAG level 1.1 mmol/l). Recently, a pooled ana-
lysis of 12 randomised controlled trials showed that plant
sterols alone modestly lower TAG levels (by 6% or
0.12 mmol/l) in hypercholesterolaemic adults depending
on baseline concentration [28]. Moreover, Micallef et al
[29] showed a 22.6% reduction in overall cardiovascular
risk of hyperlipidemic adults consuming the combination
of 2 g/day plant sterols and 1.4 g/day omega 3 PUFA com-
pared to 15.1% and 15.3% CVD risk reduction in the plant
sterols and fish oil groups alone.
A reduction in lipid levels affects plasma levels of fat
soluble vitamins [30,31]. In the present study, theconcentrations of vitamins and provitamins were un-
changed after standardisation for LDL-cholesterol levels,
except for a reduction in α- tocopherol levels.
Elevated homocysteine concentration is an independent
risk factor for ischemic stroke and thromboembolism in
children [32,33] and is strongly influenced by folate and B
vitamins status [34]. The levels of total homocysteine seen
in the present study were within the normal ranges for
both age groups agreeing with previous studies on healthy
or hypercholesterolemic children [13,34-36]. However, we
noted a significant reduction in total homocysteine by
3.25 μmol/l after 16 weeks intervention, similar to signifi-
cant reduction by 3.99 μmol/l in children with familial
hypercholesterolemia supplemented daily with 5 mg folate
for 3 months [13]. A meta-analysis of observational stud-
ies in adults suggested that lowering total homocysteine
levels by 3 μmol/l would reduce the risk of ischemic heart
disease by 11% and stroke by 19% [37]. Results for the
metabolites of the homocysteine metabolic pathway, me-
thionine and cysteine, indicate that the intervention may
have had an effect on the degradation of homocysteine
through the transsulfuration pathway to cysteine rather
than on re-methylation of homocysteine to methionine.
Cysteine may be utilised in protein synthesis or as a pre-
cursor in the synthesis of glutathione.
The pre-emulsification of fish oil significantly improves
absorption of EPA and DHA [19]. The addition of fish oil
(590 mg EPA+410 mg DHA/day) into the emulsified inter-
vention resulted in increased levels in plasma EPA by
220% and DHA by 130% and significant reduction of the
n-6 PUFAs; AA and DGLA. Engler et al [38] reported
increases in the DHA concentration and reduction in the
n-6 PUFA in the plasma phospholipids of hyperlipidemic
children after algal DHA oil supplementation (1.2 g/day).
Reducing the n-6:n-3 fatty acid ratio in the diet may
contribute to cardioprotective health in children and
adolescents.
Our pilot study has limitations; this was an investiga-
tional uncontrolled study and the observed within-group
differences may be subject to confounding factors. Also
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means that the study was underpowered to detect all stat-
istical significant differences which could explain the
observed trends for some results especially in the younger
group (10-16 years old) with only 10 participants.
Conclusions
An emulsified combination of plant sterols, fish oil and B
vitamins has beneficial effects on recognised cardiovascu-
lar risk factors in hypercholesterolemic children/adoles-
cents over a short term period following unsuccessful
attempts to alter the profiles using only dietary means.
These results are encouraging, but need to be confirmed
with a large randomised placebo controlled study.
Additional files
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lipoprotein subfractions for each subject.
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